Hims & Hers Health Inc. (HIMS) Q1 2026 (USD): EPS -0.40 (exp. 0.04), Revenue 608mln (exp. 617mln)
Guidance:
- Q2 adj. EBITDA 35-55mln (exp. 70.1mln).
- Q2 revenue 680-700mln (exp. 643mln).
- FY adj. EBITDA 275-300mln (exp. 322.8mln).
- FY revenue 2.8-3bln (exp. 2.75bln)
Context
Hims & Hers Health reported a significant miss on both earnings per share and revenue for Q1 2026, raising immediate concerns about its profitability. While the company has estimated better-than-expected revenue guidance for Q2, the adjusted EBITDA outlook falls short of expectations, highlighting potential challenges ahead that may pressure the stock. Investors should assess how these results might influence market sentiment towards HIMS and its guidance's credibility.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#METALS#US SESSION#METALS & MINING#DXY#US EQUITIES